

SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools

Funding Partners
SUMMIT is funded by IMI, which is a public/private partnership between the European Commission (EC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Each of the partners contributes with one billion EURO to the IMI budget for research grants. While the budget allocated by the EC will be exclusively awarded to beneficiaries from the public sector and to small and medium sized enterprises (SMEs), EFPIA partners will meet their budgetary obligations through in-kind contributions.
Project Partners
SUMMIT brings together the scientific expertise and clinical resources of nineteen leading universities and research institutes, six pharmaceutical companies and one SME (small and medium sized enterprise).
PARTNERS
MISSION
To DISCOVER, DEVELOP and QUALIFY potential MARKERS that empower:
-
the identification of patients at high risk of diabetes complications
-
the monitoring of the complications' progression and patients‘ response to therapy
To use the discovered markers as SURROGATE ENDPOINTS in clinical trials.
Thereby, SHORTEN the long lasting CLINICAL TRIALS to bring about EARLIER availability of NEW THERAPY to diabetic patients.